Evidence map›Paper›PMID 31341052›Full record

ArticleJournal of virology2019

The Vaccinia Virus (VACV) B1 and Cellular VRK2 Kinases Promote VACV Replication Factory Formation through Phosphorylation-Dependent Inhibition of VACV B12.

Amber B Rico, Zhigang Wang, Annabel T Olson, Alexandria C Linville, Brianna L Bullard, Eric A Weaver, Clinton Jones, Matthew S Wiebe

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Amber B RicoNebraska Center for Virology, University of Nebraska, Lincoln, Nebraska, USA.
Zhigang WangNebraska Center for Virology, University of Nebraska, Lincoln, Nebraska, USA.
Annabel T OlsonNebraska Center for Virology, University of Nebraska, Lincoln, Nebraska, USA.
Alexandria C LinvilleNebraska Center for Virology, University of Nebraska, Lincoln, Nebraska, USA.
Brianna L BullardNebraska Center for Virology, University of Nebraska, Lincoln, Nebraska, USA.
Eric A WeaverNebraska Center for Virology, University of Nebraska, Lincoln, Nebraska, USA.
Clinton JonesDepartment of Veterinary Pathobiology, Oklahoma State University Center for Veterinary Health Sciences, Stillwater, Oklahoma, USA.
Matthew S WiebeNebraska Center for Virology, University of Nebraska, Lincoln, Nebraska, USA mwiebe@unl.edu.ORCID 0000-0001-6337-6556
University of Nebraska–Lincoln · USOklahoma State University · US

Funding

Mechanism of the Antiviral Activity of BAF Against Poxvirus and HSV-1 InfectionR01AI114653 · NIAID · UNIVERSITY OF NEBRASKA LINCOLN · PI WIEBE, MATTHEW S · 2015 to 2019
$1.8M
Comparative Virology Research Training ProgramT32AI125207 · NIAID · UNIVERSITY OF NEBRASKA LINCOLN · PI WEAVER, ERIC A · 2016 to 2020
$844k
NIAID NIH HHS R01 AI114653NIAID NIH HHS T32 AI125207
6 · The paper itself

Abstract

Comparative examination of viral and host protein homologs reveals novel mechanisms governing downstream signaling effectors of both cellular and viral origin. The vaccinia virus B1 protein kinase is involved in promoting multiple facets of the virus life cycle and is a homolog of three conserved cellular enzymes called vaccinia virus-related kinases (VRKs). Recent evidence indicates that B1 and VRK2 mediate a common pathway that is largely uncharacterized but appears independent of previous VRK substrates. Interestingly, separate studies described a novel role for B1 in inhibiting vaccinia virus protein B12, which otherwise impedes an early event in the viral lifecycle. Herein, we characterize the B1/VRK2 signaling axis to better understand their shared functions. First, we demonstrate that vaccinia virus uniquely requires VRK2 for viral replication in the absence of B1, unlike other DNA viruses. Employing loss-of-function analysis, we demonstrate that vaccinia virus's dependence on VRK2 is only observed in the presence of B12, suggesting that B1 and VRK2 share a pathway controlling B12. Moreover, we substantiate a B1/VRK2/B12 signaling axis by examining coprecipitation of B12 by B1 and VRK2. Employing execution point analysis, we reveal that virus replication proceeds normally through early protein translation and uncoating but stalls at replication factory formation in the presence of B12 activity. Finally, structure/function analyses of B1 and VRK2 demonstrate that enzymatic activity is essential for B1 or VRK2 to inhibit B12. Together, these data provide novel insights into B1/VRK signaling coregulation and support a model in which these enzymes modulate B12 in a phosphorylation-dependent manner.

Indexed as

Host-Pathogen InteractionsVirus ReplicationCell LineCells, CulturedGene DeletionGene Knockdown TechniquesHumansMutationPhosphorylationProtein Serine-Threonine KinasesVacciniaVaccinia virusProtein Serine-Threonine KinasesVRK2 protein, humanB1B12DNA replicationpoxvirusprotein kinasespseudokinasesvaccinia virusvirus-host interactions

Identifiers

PMID31341052
PMCPMC6798115
OpenAlexW2963609315

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.